Core Insights - The "DREAMS series" clinical research results on Masitide have been presented at a seminar in Beijing, focusing on the endocrine and metabolic fields in China, with significant implications for global treatment strategies in obesity and diabetes [1][4]. Group 1: Research Findings - The two studies published in Nature are the DREAMS-1 study, which focuses on monotherapy for type 2 diabetes, and the DREAMS-2 study, which examines the combination of Masitide with oral hypoglycemic agents, both based on data from Chinese patients [4]. - DREAMS-1 showed that Masitide significantly improves blood sugar levels while also positively affecting weight and metabolic indicators, aligning with the evolving clinical treatment philosophy that emphasizes comprehensive management of multiple metabolic risks [4][5]. - The unique mechanism of Masitide involves dual-target action on GCG/GLP-1, which not only lowers blood sugar and controls weight but also enhances energy expenditure and improves liver lipid metabolism, catering specifically to the disease profile of Chinese patients [4]. Group 2: Clinical Implications - The DREAMS series provides clear and reliable evidence for clinical practice, emphasizing the importance of overall metabolic benefits rather than focusing solely on single endpoints, which is crucial for treatment decisions in the context of Chinese healthcare [5]. - Masitide has been approved in China for both diabetes and weight management, with ongoing phase III studies covering diabetes, obesity, and related complications, indicating its potential for broader applications in managing these conditions [5][6]. - The phase III clinical study GLORY-2 for severely obese individuals (BMI ≥ 30 kg/m²) has achieved its primary and all key secondary endpoints, and the National Medical Products Administration has accepted the application for Masitide 9mg for adult weight control [6].
减重降糖“中国方案”登《自然》主刊